Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on VIR stock, giving a Buy rating on May 22.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Roanna Ruiz’s rating is based on Vir Biotechnology’s potential to achieve significant efficacy and safety improvements with its VIR-5500 program. Despite the competition from JNJ’s pasritamig, which has shown a strong safety profile, Ruiz believes that the market for metastatic castration-resistant prostate cancer (mCRPC) is large enough to accommodate multiple T-Cell Engager (TCE) assets. Vir’s ability to dose escalate for enhanced efficacy while maintaining a favorable safety profile is a key factor in her positive outlook.
Moreover, while pasritamig presents a challenge with its convenient dosing schedule and safety, its efficacy appears modest, which could allow VIR-5500 to capture a significant market share if it can demonstrate superior results in upcoming data releases. Ruiz expects that the continued optimization of VIR-5500’s dosing regimen and the potential for improved efficacy will attract investor attention, supporting her Buy rating on the stock.
In another report released on May 22, Needham also maintained a Buy rating on the stock with a $14.00 price target.
VIR’s price has also changed moderately for the past six months – from $8.150 to $5.070, which is a -37.79% drop .